XJPX
4967
Market cap3.39bUSD
Oct 09, Last price
7,238.00JPY
1D
0.44%
1Q
30.53%
Jan 2017
44.76%
Name
Kobayashi Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Osaka, Japan, and established in 1886, Kobayashi Pharmaceutical Co., Ltd. is a global enterprise specializing in the development, manufacturing, and distribution of a wide array of consumer products. Its extensive offerings span key categories including healthcare, household necessities, skincare, and personal warming items. The company is recognized for a variety of popular brands such as Ammeltz (a topical pain reliever), Inochi no Haha (a women's health remedy), Sarasaty (lingerie soap), and Bluelet Decoral (a toilet cleaner and freshener). Their product lineup further includes Naishitol (a traditional Chinese medicine), Eaude Muge (an anti-acne medicated lotion), dental hygiene items like Itoyoji floss picks and BreathCare capsules, and eye care solutions such as Eyebon eye wash and Netsusama cooling gel sheets. Air fresheners like Sawaday and general deodorizing products, lens cleaners, and other oral hygiene items also form part of their portfolio. Beyond these, the company manufactures pharmaceuticals, quasi-drugs, cosmetics, hygiene and paper products, health foods, and processed synthetic resin products. They also market nutritional supplements and skincare directly through online and telephone channels. Complementing its core business, Kobayashi Pharmaceutical is involved in various other activities, including transportation, real estate management, advertising planning and production, and asset management.
Related entities
Subsidiaries
KOBAYASHI HEALTHCARE EUROPE LIMITED
Key people
Yoshihito Ota
Chairman of the Board · since 2025
Norikazu Toyota
President, Chief Executive Officer, Representative Director · since 2025
Yuji Matsushima
Managing Executive Officer, Chief Director in Main Research and Development Unit, Director · since 2025
Atsushi Onoyama
Managing Executive Officer, Chief Director in Main Marketing Unit · since 2025
Koji Akita
Executive Officer, Chief Director of International Business · since 2025
Ryo Ishido
Executive Officer, Chief Director in Main DX Unit · since 2025
Executive Officer, Chief Director of Public Relations and General Affairs · since 2025
Kenji Kobori
Executive Officer, Chief Director of Sales · since 2024
Takuya Matsushita
Executive Officer, Director of China Strategy in International Business Unit · since 2023
Yumi Nakagawa
Executive Officer, Chief Director in Main Finance Unit · since 2025
Hiroya Nakamura
Executive Officer, Chief Director of Production · since 2025
Kei Sato
Executive Officer, Chief Director in Main Compensation Response Unit · since 2024
Hiroo Yamasaki
Executive Officer, Chief Director of Product Quality Assurance Unit · since 2025
Akihiro Kobayashi
Executive Officer, Director · since 2024
Toshiaki Kadokawa
Independent Director · since 2025
Yoshiro Katae
Independent Director · since 2022
Misa Kusumoto
Independent Director · since 2025
Shinsuke Matsumoto
Independent Director · since 2025
Masato Mori
Independent Director · since 2025
Akio Takahashi
Independent Director · since 2025
Headquarters & legal address
中央区道修町4丁目4番10号
大阪市, 27 541-0045
JP
大阪市, 27 541-0045
JP
Other language
Kobayashi Pharmaceutical Co. Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||